Dalbonova — Dalbavancin
Dalbavancin's biggest clinical advantage isn't just that it's effective against gram-positive bacteria including MRSA — it's that its long-acting profile allows treatment with just one or two doses instead of the daily IV infusions required by conventional antibiotics for skin infections, a genuine operational advantage for hospitals looking to reduce the inpatient bed-days typically needed for extended antibiotic courses.
- Approved indications: Acute bacterial skin and skin-structure infections (ABSSSI) in adults and children as young as 3 months, including infections caused by MRSA
- Mechanism: A glycopeptide antibiotic that inhibits bacterial cell-wall synthesis by binding to peptidoglycan, making it particularly effective against gram-positive bacteria that have thick peptidoglycan layers
- Dosing advantage: Typically administered as a single dose or two-dose regimen given a week apart, compared to conventional antibiotics requiring daily dosing for one to two weeks — a genuine cost and hospital-resource advantage worth highlighting to procurement teams
- Buyer profile: Hospital infectious-disease and emergency-medicine departments looking to reduce extended-antibiotic-course inpatient costs
Key Product Facts
500mg (25mL vial)
Strength
Single-dose vial
Pack Size
Dalbavancin
Active Ingredient
Anti-Infectives
Category
On Request
Availability
Dalbavancin's biggest clinical advantage isn't just that it's effective against gram-positive bacteria including MRSA — it's that its long-acting profile allows treatment with just one or two doses instead of the daily IV infusions required by conventional antibiotics for skin infections, a genuine operational advantage for hospitals looking to reduce the inpatient bed-days typically needed for extended antibiotic courses.
- Approved indications: Acute bacterial skin and skin-structure infections (ABSSSI) in adults and children as young as 3 months, including infections caused by MRSA
- Mechanism: A glycopeptide antibiotic that inhibits bacterial cell-wall synthesis by binding to peptidoglycan, making it particularly effective against gram-positive bacteria that have thick peptidoglycan layers
- Dosing advantage: Typically administered as a single dose or two-dose regimen given a week apart, compared to conventional antibiotics requiring daily dosing for one to two weeks — a genuine cost and hospital-resource advantage worth highlighting to procurement teams
- Buyer profile: Hospital infectious-disease and emergency-medicine departments looking to reduce extended-antibiotic-course inpatient costs
- Infusion-related reactions: Rapid infusion can cause reactions similar to "Red Man Syndrome" — slow infusion rate is recommended to minimize this risk
- Renal caution: Dose consideration needed in patients with kidney impairment, particularly elderly patients
- Diarrhea: Including risk of C. difficile-associated diarrhea, as with most antibiotics
- Hepatic caution: Patients with liver disorders should be monitored
- Pregnancy/breastfeeding: Consult physician — safety not fully established
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: Standard export logistics
- Coverage: Global export markets
- Tracking: Full shipment tracking included
What is Dalbavancin used for?
Treats acute bacterial skin and skin-structure infections, including those caused by MRSA.
Get Dalbavancin price from a GMP-compliant Indian supplier — how?
Send required quantity and destination for a verified quote.
How many doses are typically needed?
Often just one or two doses, compared to daily antibiotics required for one to two weeks with conventional treatment.
Can children receive it?
Yes, it's approved for use in children as young as 3 months.
Who supplies Dalbavancin from India?
WHO-GMP certified manufacturer with full export documentation.
